Tern deepens Talking Medicines bet with fresh convertible, lifts payout pledge to 70%
What's the deal? Tern has invested in additional Talking MedicinesDealroom has a profile for this one. Try Dealroom → convertible loan notes, increasing its funding to the portfolio company. The firm also raised its minimum shareholder distribution commitment to 70% on qualifying exits.
Why now? The move is a quick re-raise, with Tern topping up its position in Talking Medicines soon after its earlier backing. The convertible structure lets Tern add capital now and convert to equity later.
What's the endgame? By committing to distribute at least 70% of proceeds from qualifying exits to shareholders, Tern signals confidence in its portfolio while tying its own returns more closely to investor payouts.
The signal: A follow-on convertible paired with a higher payout pledge points to a firm doubling down on an existing bet rather than chasing new deals — and betting that Talking Medicines can deliver an exit worth sharing.
Read more: DirectorsTalk Interviews
Image credit: National Institutes of Health (NIH)
